KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Intangibles (2015 - 2025)

Gsk (GSK) posted Intangibles of $22.3 billion for Q4 2025, up 11.87% on a QoQ basis from $19.9 billion in Q4 2024, and up 11.87% year-over-year from $19.9 billion in Q4 2024.

Gsk (GSK) has 11 years of Intangibles data on file, last reported at $22.3 billion in Q4 2025.

  • In Q4 2025, Intangibles rose 11.87% year-over-year to $22.3 billion; the TTM figure through Dec 2025 stood at $22.3 billion (up 11.87% YoY), while the FY2025 annual figure was $22.3 billion, up 11.87% from the prior year.
  • Intangibles advanced to $22.3 billion in Q4 2025, from $19.9 billion in the prior quarter.
  • Across five years, Intangibles topped out at $40.5 billion in Q4 2021 and bottomed at $16.8 billion in Q4 2022.
  • A 5-year average of $23.6 billion and a median of $19.9 billion in 2024 frame the typical range for Intangibles.
  • Annual changes were most pronounced in 2022 — Intangibles slumped 58.58% — and 2025, when it advanced 11.87%.
  • Year by year, Intangibles stood at $40.5 billion in 2021, then slumped by 58.58% to $16.8 billion in 2022, then gained by 9.14% to $18.3 billion in 2023, then increased by 8.64% to $19.9 billion in 2024, then increased by 11.87% to $22.3 billion in 2025.
  • The last three Intangibles figures came in at $22.3 billion (Q4 2025), $19.9 billion (Q4 2024), and $18.3 billion (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Intangibles (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 7.37 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 49.06 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 50.87 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn 25.75 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 21.38 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 16.38 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn 52.56 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 18.24 Bn
10 Gsk 88.34 Bn 83.66 Bn - 22.28 Bn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 22.28 Bn
Dec 31, 2024 19.91 Bn
Dec 31, 2023 18.33 Bn
Dec 31, 2022 16.79 Bn
Jun 30, 2022 25.13 Bn
Dec 31, 2021 40.55 Bn
Dec 31, 2020 39.38 Bn
Dec 31, 2019 39.80 Bn
Dec 31, 2018 22.13 Bn
Dec 31, 2017 23.32 Bn
Dec 31, 2016 23.34 Bn
Dec 31, 2015 25.30 Bn